Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

被引：38

作者：

Kaneko, Shuichi ^{[1
,2
,3
]}

Furuse, Junji ^{[1
,2
,4
]}

Kudo, Masatoshi ^{[1
,2
,5
]}

Ikeda, Kenji ^{[1
,2
,6
]}

Honda, Masao ^{[2
,5
]}

Nakamoto, Yasunari ^{[2
,7
]}

Onchi, Morikazu ^{[2
,8
]}

Shiota, Goshi ^{[2
,9
]}

Yokosuka, Osamu ^{[2
,10
]}

Sakaida, Isao ^{[2
,11
]}

Takehara, Tetsuo ^{[2
,12
]}

Ueno, Yoshiyuki ^{[2
,13
]}

Hiroishi, Kazumasa ^{[2
,14
]}

Nishiguchi, Shuhei ^{[2
,15
]}

Moriwaki, Hisataka ^{[2
,16
]}

Yamamoto, Kazuhide ^{[2
,17
]}

Sata, Michio ^{[2
,18
]}

Obi, Shuntaro ^{[2
,19
]}

Miyayama, Shiro ^{[2
,20
]}

Imai, Yukinori ^{[2
,21
]}

机构：

[1] Kanazawa Univ, Novel Anticanc Agent Guideline Drafting Comm, Kanazawa, Ishikawa, Japan

[2] Kanazawa Univ, Study Grp New Liver Canc Therapies, Kanazawa, Ishikawa, Japan

[3] Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa, Japan

[4] Kyorin Univ, Sch Med, Dept Med Oncol, Mitaka, Tokyo 181, Japan

[5] Kinki Univ, Dept Gastroenterol, Higashiosaka, Osaka 577, Japan

[6] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan

[7] Univ Fukui, Grad Sch Med, Dept Gastroenterol, Fukui 910, Japan

[8] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Matsuyama, Ehime, Japan

[9] Tottori Univ, Grad Sch Med, Div Mol & Genet Med, Tottori 680, Japan

[10] Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan

[11] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Yamaguchi, Japan

[12] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[13] Tohoku Univ, Grad Sch Med, Dept Gastroenterol, Sendai, Miyagi 980, Japan

[14] Showa Univ, Sch Med, Dept Med, Div Gastroenterol, Tokyo 142, Japan

[15] Hyogo Coll Med, Dept Internal Med, Div Hepatobiliary & Pancreat Dis, Kakogawa, Hyogo, Japan

[16] Gifu Univ, Grad Sch Med, Dept Gastroenterol, Gifu, Japan

[17] Okayama Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Okayama, Japan

[18] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 830, Japan

[19] Kyoundo Hosp, Dept Hepatol, Tokyo, Japan

[20] Fukuiken Saiseikai Hosp, Dept Diagnost Radiol, Fukui, Japan

[21] Saitama Med Univ, Fac Med, Dept Gastroenterol & Hepatol, Saitama, Japan

来源：

HEPATOLOGY RESEARCH | 2012年 / 42卷 / 06期

基金：

日本学术振兴会;

关键词：

hepatic arterial infusion; hepatocellular carcinoma; miriplatin; molecular targeting therapy; sorafenib; MULTIKINASE INHIBITOR SORAFENIB; PHASE-II; SYSTEMIC THERAPY; TRIAL; SM-11355; CRITERIA;

D O I：

10.1111/j.1872-034X.2012.00981.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma was prepared by the Study Group on New Liver Cancer Therapies established by the Research Project on Emergency Measures to Overcome Hepatitis under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents clinical questions on issues pertaining to medical care, makes recommendations on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of scientific statements.

引用

页码：523 / 542

页数：20

共 35 条

[31] Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib
Spira, Daniel
Fenchel, Michael
Lauer, Ulrich M.
Claussen, Claus D.
Gregor, Michael
Bitzer, Michael
Horger, Marius
[J]. ACADEMIC RADIOLOGY, 2011, 18 (01) : 89 - 96
[32] Ueshima K, 2010, KANZO, V51, P681
[33] Yamashita Y, 1987, Radiat Med, V5, P61
[34] Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study
Zhang, Zhe
Zhou, Xiaoyun
Shen, Hujia
Wang, Dexing
Wang, Yanhong
[J]. BMC MEDICINE, 2009, 7
[35] Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study
Zhao, Jian-Dong
Liu, Jin
Ren, Zhi-Gang
Gu, Ke
Zhou, Zhen-Hua
Li, Wen-Tao
Chen, Zhen
Xu, Zhi-Yong
Liu, Lu-Ming
Jiang, Guo-Liang
[J]. RADIATION ONCOLOGY, 2010, 5

← 1 2 3 4 →